Impact of preformed donor-specific antibodies against HLA class I on kidney graft outcomes: Comparative analysis of exclusively anti-Cw vs anti-A and/or -B antibodies

Table 2 Clinical outcomes and follow-up

	DSA-A-Bn = 23	DSA-Cwn = 12	P
Delayed graft function, n (%)	7 (30)	1 (8)	0.216
Acute rejection at 1-yr, n (%)	6 (26)	3 (25)	1
AMR at 1-yr, n (%)	6 (26)	2 (17)	0.685
ACR-only at 1-yr, n (%)	0	1 (8)	0.343
1 yr-eGFR (mL/min), median (IQR)	51 (46-60)	59 (47-64)	0.192
1 yr-ProtU, median (IQR)	0 (0-0.1)	0.1 (0-0.2)	0.163
Censored graft failure, n (%)	2 (9)	0	0.536
Follow-up time (mo), median (IQR) [range]	60 (45-60)	18 (11-50)	0.001
	[28-60]	[3-60]

DSA: Donor-specific antibodies; AMR: Acute antibody-mediated rejection; ACR: Acute cellular rejection; eGFR: Estimated glomerular filtration rate; IQR: Interquartile range; ProtU: Proteinuria.